Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Two choices of drugs that reduce CV risk in T2DM
Two choices of drugs that reduce CV risk in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Two choices of drugs that reduce CV risk in T2DM
- Prof. John Deanfield, MD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The GLP1 landscape - refining our understanding
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The GLP1 landscape - refining our understanding
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
- Prof. Lars Rydén
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?